AT-7519

AT-7519 is an orally bioavailable small molecule that acts as a selective inhibitor of multiple cyclin-dependent kinases (CDKs), including CDK1, CDK2, CDK4, CDK6, and CDK9. By inhibiting these serine/threonine kinases—which are key regulators of the cell cycle—AT‑7519 induces cell cycle arrest and apoptosis in tumor cells. It has demonstrated antineoplastic activity in preclinical models and early-phase clinical trials. Developed by Astex Therapeutics/Astex Pharmaceuticals for the treatment of various cancers, its primary indications have included chronic lymphocytic leukemia, mantle-cell lymphoma, multiple myeloma (all Phase II), as well as solid tumors (Phase I). The drug is administered intravenously[1][2][3][4][5][6].

Other names

4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide